OvaScience (OVAS) Receiving Somewhat Positive Media Coverage, Study Finds
News stories about OvaScience (NASDAQ:OVAS) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OvaScience earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.0308850650407 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- OvaScience to Host Third Quarter 2017 Financial Results Conference Call – Business Wire (press release) (businesswire.com)
- Zacks: Analysts Anticipate OvaScience Inc. (OVAS) Will Post Quarterly Sales of $90,000.00 (americanbankingnews.com)
- MDRejuvena, Inc. announces the addition of Mary Fisher to the Company’s Board of Directors (bizjournals.com)
- OvaScience Inc. (OVAS) to Release Earnings on Wednesday (americanbankingnews.com)
A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered OvaScience from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of OvaScience in a report on Thursday, August 3rd.
OvaScience (NASDAQ:OVAS) opened at 1.52 on Wednesday. OvaScience has a 52 week low of $1.25 and a 52 week high of $5.10. The firm’s 50-day moving average price is $1.43 and its 200-day moving average price is $1.45. The company’s market capitalization is $54.24 million.
OvaScience (NASDAQ:OVAS) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.02. OvaScience had a negative net margin of 16,132.47% and a negative return on equity of 69.13%. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter in the previous year, the company posted ($0.62) EPS. OvaScience’s revenue was down 55.6% on a year-over-year basis. On average, equities analysts expect that OvaScience will post ($1.70) earnings per share for the current year.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.